Compare Amgen, Inc. (AMGN) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs LyondellBasell Industries NV — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while LyondellBasell Industries NV trades at $57.31 (market cap $18.19B). The key difference: Amgen, Inc. is far larger — about 10.8× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.31%). Which is the better fit depends on your goals.
| AMGN | LYB | |
|---|---|---|
Market Cap | $196.12B | $18.19B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $82.38 |
52-Week Low | $271.18 | $42.28 |
Enterprise Value | $241.41B | $29.81B |
Dividend Yield | 2.77% | 7.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LYB trades at $56.36, up 1.74% today, with a bearish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows declining revenue and negative net income margins, though it maintains positive operating cash flow and recently announced a partnership for recycled-content packaging with Mondelez. Analyst consensus is a Buy with a $73.11 price target, indicating potential upside from current levels.
Outlook remains cautious due to profitability challenges and elevated debt, but cost-cutting and strategic shifts toward higher-margin polymers offer recovery potential. Key risks include persistent margin pressure and macroeconomic sensitivity, while institutional sentiment is divided between growth optimism and fundamental concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
